The Bismuth–Corlette classification system provides an anatomic description ... They often manifest as a concentric thickening of the bile duct, coupled with infiltration of the periductal ...

EGF receptor (EGFR), VEGF and human EGF receptor 2 (HER2) have been considered as potential therapeutic targets in cholangiocarcinoma ... the VEGF/VEGFR system is an interesting target for ...

Bile duct cancer, or cholangiocarcinoma, is a malignant tumour of either the bile ducts within the liver (intrahepatic), or those leading from the liver to the small intestine (extrahepatic).

Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved by the FDA, thanks to a clinical trial co-led by MSK.

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

The agency has approved Ziihera for adults with previously treated, unresectable or metastatic HER2-positive biliary tract ...

The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand ...